RXRα suppression drives hepatic metabolic and immune dysfunction in sepsis.

Summary

This mechanistic study shows that hepatocyte RXRα maintains metabolic stability and antibacterial defense during polymicrobial sepsis. Prophylactic, but not therapeutic, bexarotene improved survival in mice, and hepatocyte-specific RXRα loss reduced Kupffer cells, leading to bacterial dissemination and mortality.

Key Findings

• Sepsis rapidly downregulates hepatocyte RXRα at mRNA and protein levels under HNF4α control.
• Prophylactic, but not therapeutic, bexarotene improves survival by preserving metabolic stability and bacterial clearance.
• Hepatocyte-specific RXRα loss depletes Kupffer cells, driving bacterial dissemination and mortality, linking hepatocellular competence to hepatic macrophage niches.

Clinical Implications

Hepatocyte RXRα emerges as a potential target to preserve hepatic immune-metabolic fitness in early sepsis. Timing appears critical; prophylactic/very-early activation may help, whereas later activation may be ineffective, guiding trial design and biomarker-driven patient selection.

Limitations

• Protective effects observed only with prophylactic bexarotene; septic liver showed partial pharmacologic resistance.
• Preclinical models; human translatability, dosing, and timing remain to be established.

Future Directions

Define optimal timing and ligands for RXRα activation, develop biomarkers of hepatic RXRα activity, and test RXRα-targeted strategies in early-phase, time-sensitive clinical trials.